.png){kind=icon}
.png){kind=icon}
Return
Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO)
.png){kind=icon}
PRE
AI
Y
J
D
W
Z
H
Y
G
H
W
Y
DOI：10.1016/j.medj.2026.101183.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Tirzepatide monotherapy significantly improved glycemic control vs. placebo • Tirzepatide led to robust body weight reductions compared with placebo • Tirzepatide did not increase the risk of clinically meaningful or severe hypoglycemia • The safety profile was consistent with previous studies of tirzepatide
Journal
IF:
11.8
Papers:
771
Citations:
2.2K
Organization
Cited Papers